The Food and Drug Administration yesterday alerted health care professionals and patients not to use drug products produced by Cantrell Drug Co., including opioid products and other drugs intended for sterile injection, citing serious deficiencies in the company’s compounding operations. “Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs without adequately addressing their potentially dangerous conditions,” said FDA Commissioner Scott Gottlieb, M.D. “This reckless activity threatens patient safety and will not be tolerated.” FDA has sought legal action to prevent the company from further producing and distributing drugs. It said health care professionals should immediately check their medical supplies, quarantine any drug products from the company and not administer them to patients. The agency is not aware of illness reports associated with the products, but asks health care professionals to report any associated adverse events or quality problems to its MedWatch program.

Related News Articles

Headline
The Centers for Medicare…
Headline
The AHA’s Institute for Diversity and Health Equity today named Duane Elliott Reynolds as its new president and CEO.
Blog
Axios' The poor state of U.S hospital quality (December 1, 2018) gives an incomplete view on the state of quality and safety in America’s hospitals and health…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
Inpatient rehabilitation facilities and long-term care hospitals have until Jan. 2 to review confidential provider reports based on quality data from second-…
Headline
The Institute for Healthcare Improvement today released a white paper intended to help health system boards assess and improve their quality oversight…